期刊文献+

血清肿瘤标志物在肺癌中的检测和临床意义 被引量:4

Detection and clinical significance of measurement of serum tumor markers in patients with lung cancer
下载PDF
导出
摘要 目的探讨4种血清肿瘤标志物糖链抗原125Ⅱ(CA125Ⅱ)、细胞角质素片断抗原(CYFRA21-1)、癌胚抗原(CEA)及神经元特异性烯醇酶(NSE)在肺癌辅助诊断中的应用价值和意义,并选择最理想的血清肿瘤标志物组合。方法用电化学发光免疫法(ECLIA)测定48例肺部良性病变、89例晚期肺癌患者血清CA125Ⅱ、CYFRA21-1、CEA及NSE的水平。结果肺癌患者的4种血清肿瘤标志物水平均明显高于肺部良性疾病组,有显著性差异(P<0.01)。CYFRA21-1在鳞癌中阳性率最高,明显高于其他类型的肺癌(P<0.01)。CA125Ⅱ、CEA在腺癌中阳性率最高,NSE则在小细胞癌(SCLC)最为明显。结论合理利用血清肿瘤标志物检查肺癌患者,既有助于诊断,又可做到合理检查、避免资源浪费。 Objective To evaluate the clinical value and significance of four serum tumor markers CA125 Ⅱ , CYFRA21 - 1, CEA and NSE used alone or in combination in assistant diagnosis of lung cancer. Methods The level of four serum tumor markers were detected by electrochemiluminescence immunoassay (ECLIA) in 48 benign lung diseases(BLD), 89 lung cancer patients in advanced stage (20 SCLC and 69 NSCLC). Results The level of the four serum tumor markers in lung cancer patients was significantly higher than those in BLD group ( P 〈 0.01). The level of CYFRA21 - 1 in patients with squamous- cell carcinoma was significantly higher than that in other subtypes ( P 〈 0.01 ). The level of CA125 Ⅱ and CEA in patients with glandular carcinoma was significantly higher than that in other subtypes ( P 〈0.05). The level of NSE in patients with small - cell lung cancer was significantly higher than those in the other subtypes of lung cancer ( P 〈 0.01 ). Utilizing serum tumor markers reasonably to detect lung cancer patients was not only better for diagnose, but also for reasonable detection and avoiding wasting resources.
出处 《宁夏医学杂志》 CAS 2007年第2期118-120,共3页 Ningxia Medical Journal
关键词 肺癌 肿瘤标志物 Lung cancer Serum tumor marker
  • 相关文献

参考文献10

  • 1沈洪兵,俞顺章.我国肺癌流行现状及其预防对策[J].中国肿瘤,2004,13(5):283-285. 被引量:139
  • 2汤钊猷主编..现代肿瘤学 第2版[M],2000:1507.
  • 3Stieber P,Zmmermanm A,Reinmiedi J,et al.CYFRA21-1 in the early diagnosis of recurrent disease in non small cell lung carcinoma(SCLC)[J].Anticancer Research,1999,19:2665-2668. 被引量:1
  • 4Takada M,Masuda N,Matsuura E,et al.Measurement of cytokeratin1 19 fragments as a marker of lung cancer by CYFRA2 1-1 enzyme immunoassay[J].Br J Cancer,1995,71:160-165. 被引量:1
  • 5胡艳萍,钟爱军,杨小玲,周运华,杨玲,柯玉华.晚期非小细胞肺癌患者血清CA125水平的预后价值[J].中华肿瘤杂志,2000,22(1):30-31. 被引量:42
  • 6Ando S,Kimura H,Iwai N,et al.Positive reaction for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer[J].Anticancer Res,2003,23(3):2869-2874. 被引量:1
  • 7Diez M,Cerlan F,Ortega M,et al.Evaluation of serum CA125 as a tumor marker in non-small cell lung cancer[J].Cancer,1991,67:150-154. 被引量:1
  • 8Ebert W,Muley T,Raine C,et al.Comparision of changes in the NSE levels with clinical assessmet in the therapy monitoring of patients with SCLC[J].Auticancer Res,2002,22(28):1083-1085. 被引量:1
  • 9Shibayama T,Vecka H,Nishiik G,et al.Complementary roles of pro-gastrin-releasing peptide(proGRP) and nearcific enolase(NSE) in diagnosis and prognosis of small-cell lung cancer(SCLC)[J].Lung Cancer,2001,32(1):61-63. 被引量:1
  • 10赵先文 ,韩存芝 ,荆洁线 ,杜丽莉 ,田保国 ,李国栋 ,张中书 .肺癌患者血清肿瘤标志物联合检测及临床意义[J].肿瘤研究与临床,2005,17(3):170-172. 被引量:26

二级参考文献24

共引文献201

同被引文献27

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部